Osteocalcin levels in patients with microprolactinoma before and during medical treatment

A. Sartorio, A. Conti, B. Ambrosi, M. Muratori, F. Morabito, G. Faglia

Research output: Contribution to journalArticle

Abstract

Osteocalcin (OC) concentration, a specific index of bone formation, was measured in 29 female patients with microprolactinoma (serum prolactin, PRL: 105 ± 10.9 ng/ml; mean ± SE). Mean OC levels were significantly lower than in controls (1.7 ± 0.2 vs 5.1 ± 0.3 ng/ml; p <0.001), being below the normal range in 28 out of 29 patients. All patients were treated with dopaminergic agents (dihydroergocriptine, bromocriptine or cabergoline). After treatment mean serum PRL levels were significantly reduced (12 ± 3.1 ng/ml; p <0.001), a full normalization being obtained in 26 patients. There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergo-line. Serum OC levels significantly increased after 12 month therapy (4.7 ± 0.6 ng/ml, p <0.001), a normal concentration being reached in 14 of 29 cases. During treatment there were no significant differences in serum estradiol and PRL concentrations between patients who normalized or not their OC levels, while the reduction in PRL levels with respect to baseline was more pronounced in the former group. The absolute increase in OC levels positively correlated with serum PRL decrements (p <0.01). It is noteworthy that serum OC normalized in 1/10 patients during dihydroergocriptine, 3/8 during bromocriptine and 10/11 during cabergoline. Four patients, previously treated with dihydroergocriptine and bromocriptine without normalizing OC and PRL levels, underwent a second course of therapy with cabergoline and then normalized OC concentrations. In conclusion, these preliminary data show that i) OC levels are reduced in women with microprolactinoma, ii) after successful treatment of hyperprolactinemia a recovery of osteoblastic activity frequently occurs. Further investigations on the actions of dopaminergic drugs are needed, in view of their different effects on OC concentrations. Tresented in part at the 7th International Congress on calciotropic hormones and calcium metabolism, Salsomaggiore, Italy, October 1988.

Original languageEnglish
Pages (from-to)419-422
Number of pages4
JournalJournal of Endocrinological Investigation
Volume13
Issue number5
DOIs
Publication statusPublished - 1990

Fingerprint

Prolactinoma
Osteocalcin
Bromocriptine
Serum
Therapeutics
Dopamine Agents
Hyperprolactinemia
Osteogenesis
Prolactin
Italy
Estradiol
Reference Values
Hormones
Calcium

Keywords

  • bone formation
  • dopaminergic agents
  • Osteocalcin
  • prolactin
  • prolactinoma

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Osteocalcin levels in patients with microprolactinoma before and during medical treatment. / Sartorio, A.; Conti, A.; Ambrosi, B.; Muratori, M.; Morabito, F.; Faglia, G.

In: Journal of Endocrinological Investigation, Vol. 13, No. 5, 1990, p. 419-422.

Research output: Contribution to journalArticle

Sartorio, A. ; Conti, A. ; Ambrosi, B. ; Muratori, M. ; Morabito, F. ; Faglia, G. / Osteocalcin levels in patients with microprolactinoma before and during medical treatment. In: Journal of Endocrinological Investigation. 1990 ; Vol. 13, No. 5. pp. 419-422.
@article{b883a5a773454c838452d15c02ace263,
title = "Osteocalcin levels in patients with microprolactinoma before and during medical treatment",
abstract = "Osteocalcin (OC) concentration, a specific index of bone formation, was measured in 29 female patients with microprolactinoma (serum prolactin, PRL: 105 ± 10.9 ng/ml; mean ± SE). Mean OC levels were significantly lower than in controls (1.7 ± 0.2 vs 5.1 ± 0.3 ng/ml; p <0.001), being below the normal range in 28 out of 29 patients. All patients were treated with dopaminergic agents (dihydroergocriptine, bromocriptine or cabergoline). After treatment mean serum PRL levels were significantly reduced (12 ± 3.1 ng/ml; p <0.001), a full normalization being obtained in 26 patients. There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergo-line. Serum OC levels significantly increased after 12 month therapy (4.7 ± 0.6 ng/ml, p <0.001), a normal concentration being reached in 14 of 29 cases. During treatment there were no significant differences in serum estradiol and PRL concentrations between patients who normalized or not their OC levels, while the reduction in PRL levels with respect to baseline was more pronounced in the former group. The absolute increase in OC levels positively correlated with serum PRL decrements (p <0.01). It is noteworthy that serum OC normalized in 1/10 patients during dihydroergocriptine, 3/8 during bromocriptine and 10/11 during cabergoline. Four patients, previously treated with dihydroergocriptine and bromocriptine without normalizing OC and PRL levels, underwent a second course of therapy with cabergoline and then normalized OC concentrations. In conclusion, these preliminary data show that i) OC levels are reduced in women with microprolactinoma, ii) after successful treatment of hyperprolactinemia a recovery of osteoblastic activity frequently occurs. Further investigations on the actions of dopaminergic drugs are needed, in view of their different effects on OC concentrations. Tresented in part at the 7th International Congress on calciotropic hormones and calcium metabolism, Salsomaggiore, Italy, October 1988.",
keywords = "bone formation, dopaminergic agents, Osteocalcin, prolactin, prolactinoma",
author = "A. Sartorio and A. Conti and B. Ambrosi and M. Muratori and F. Morabito and G. Faglia",
year = "1990",
doi = "10.1007/BF03350694",
language = "English",
volume = "13",
pages = "419--422",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "5",

}

TY - JOUR

T1 - Osteocalcin levels in patients with microprolactinoma before and during medical treatment

AU - Sartorio, A.

AU - Conti, A.

AU - Ambrosi, B.

AU - Muratori, M.

AU - Morabito, F.

AU - Faglia, G.

PY - 1990

Y1 - 1990

N2 - Osteocalcin (OC) concentration, a specific index of bone formation, was measured in 29 female patients with microprolactinoma (serum prolactin, PRL: 105 ± 10.9 ng/ml; mean ± SE). Mean OC levels were significantly lower than in controls (1.7 ± 0.2 vs 5.1 ± 0.3 ng/ml; p <0.001), being below the normal range in 28 out of 29 patients. All patients were treated with dopaminergic agents (dihydroergocriptine, bromocriptine or cabergoline). After treatment mean serum PRL levels were significantly reduced (12 ± 3.1 ng/ml; p <0.001), a full normalization being obtained in 26 patients. There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergo-line. Serum OC levels significantly increased after 12 month therapy (4.7 ± 0.6 ng/ml, p <0.001), a normal concentration being reached in 14 of 29 cases. During treatment there were no significant differences in serum estradiol and PRL concentrations between patients who normalized or not their OC levels, while the reduction in PRL levels with respect to baseline was more pronounced in the former group. The absolute increase in OC levels positively correlated with serum PRL decrements (p <0.01). It is noteworthy that serum OC normalized in 1/10 patients during dihydroergocriptine, 3/8 during bromocriptine and 10/11 during cabergoline. Four patients, previously treated with dihydroergocriptine and bromocriptine without normalizing OC and PRL levels, underwent a second course of therapy with cabergoline and then normalized OC concentrations. In conclusion, these preliminary data show that i) OC levels are reduced in women with microprolactinoma, ii) after successful treatment of hyperprolactinemia a recovery of osteoblastic activity frequently occurs. Further investigations on the actions of dopaminergic drugs are needed, in view of their different effects on OC concentrations. Tresented in part at the 7th International Congress on calciotropic hormones and calcium metabolism, Salsomaggiore, Italy, October 1988.

AB - Osteocalcin (OC) concentration, a specific index of bone formation, was measured in 29 female patients with microprolactinoma (serum prolactin, PRL: 105 ± 10.9 ng/ml; mean ± SE). Mean OC levels were significantly lower than in controls (1.7 ± 0.2 vs 5.1 ± 0.3 ng/ml; p <0.001), being below the normal range in 28 out of 29 patients. All patients were treated with dopaminergic agents (dihydroergocriptine, bromocriptine or cabergoline). After treatment mean serum PRL levels were significantly reduced (12 ± 3.1 ng/ml; p <0.001), a full normalization being obtained in 26 patients. There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergo-line. Serum OC levels significantly increased after 12 month therapy (4.7 ± 0.6 ng/ml, p <0.001), a normal concentration being reached in 14 of 29 cases. During treatment there were no significant differences in serum estradiol and PRL concentrations between patients who normalized or not their OC levels, while the reduction in PRL levels with respect to baseline was more pronounced in the former group. The absolute increase in OC levels positively correlated with serum PRL decrements (p <0.01). It is noteworthy that serum OC normalized in 1/10 patients during dihydroergocriptine, 3/8 during bromocriptine and 10/11 during cabergoline. Four patients, previously treated with dihydroergocriptine and bromocriptine without normalizing OC and PRL levels, underwent a second course of therapy with cabergoline and then normalized OC concentrations. In conclusion, these preliminary data show that i) OC levels are reduced in women with microprolactinoma, ii) after successful treatment of hyperprolactinemia a recovery of osteoblastic activity frequently occurs. Further investigations on the actions of dopaminergic drugs are needed, in view of their different effects on OC concentrations. Tresented in part at the 7th International Congress on calciotropic hormones and calcium metabolism, Salsomaggiore, Italy, October 1988.

KW - bone formation

KW - dopaminergic agents

KW - Osteocalcin

KW - prolactin

KW - prolactinoma

UR - http://www.scopus.com/inward/record.url?scp=0025325120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025325120&partnerID=8YFLogxK

U2 - 10.1007/BF03350694

DO - 10.1007/BF03350694

M3 - Article

C2 - 1974270

AN - SCOPUS:0025325120

VL - 13

SP - 419

EP - 422

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 5

ER -